Pharmaceutical Career Guide

Explore pharmaceutical industry jobs, salaries and career paths across discovery, clinical development, regulatory affairs, manufacturing and commercial. Get interview preparation and stay current on approvals, trials and drug pricing.

How we research our career guides

The Top Pharma News, in 5 Minutes.

We handpick the best pharmaceutical industry newsletters and distill the readouts, approvals, deals and pricing decisions into a 5-minute audio briefing, delivered by text every morning.

Try Our Pharma BriefingFree
See the 4 newsletters we handpicked

At a glance

The Pharmaceutical Industry at a Glance

Federal statistics do not record a pharmaceutical occupation, so the industry has to be read across several codes: 181,000 medical scientists at a median of $103,410, 93,500 chemists and materials scientists at $95,060, 74,400 biological technicians at $57,510, 35,200 biochemists and biophysicists at $127,410, 252,100 industrial production managers at $126,060 and 112,200 natural sciences managers at $167,220. The common picture of the industry, a chemist at a bench, covers a narrow slice of it. Most pharmaceutical work is the machinery around a molecule: clinical operations staff who run the trials, data managers who define and clean the endpoints, medical writers who assemble the submission, regulatory affairs professionals who negotiate with the agencies, process development and CMC scientists who make the drug at scale, quality staff who own the systems that keep it lawful, pharmacovigilance teams who collect and assess safety reports, medical science liaisons who talk to physicians, and market access specialists who argue the price. Pay follows scope rather than seniority, and the highest medians belong to people leading the work rather than running the assays. Entry is usually a bachelor's degree, with doctorates concentrated in discovery and translational science, and the industry takes people arriving from clinical practice, statistics, law and the factory floor. The direction of travel is set outside any one company: what regulators accept as evidence, and what payers will fund.

Key Industry Statistics

46

Novel drugs FDA's CDER approved in 2025US Food and Drug Administration

$103,410

Median annual pay, medical scientists (May 2025)US Bureau of Labor Statistics

6 to 10 months

FDA review clock once an application is filedUS Food and Drug Administration

33%

Phase 2 drugs that advance to phase 3US Food and Drug Administration

Common roles

  • Clinical Research Associate
  • Regulatory Affairs Manager
  • Medical Science Liaison
  • Clinical Data Manager
  • Process Development Scientist
  • Quality Assurance Manager

Where the work happens

  • Large pharmaceutical companies
  • Contract research organisations
  • Contract manufacturers
  • Generics and specialty makers
  • Regulatory agencies
  • Consultancies and medical communications

Credentials that matter

  • RAC-Drugs
  • ACRP certification
  • PhD, PharmD or MD
  • Project management certification
  • Quality and audit credentials

Key Areas in the Pharmaceutical Industry

  • Discovery & Medicinal Chemistry

    Finding and optimising compounds against a target, from screening hits to a development candidate.

  • Preclinical & Toxicology

    Laboratory and animal work under good laboratory practice that establishes dosing and toxicity.

  • Clinical Development & Operations

    Designing, running and monitoring trials through phases one to three, auditably and on time.

  • Regulatory Affairs

    Owning the submission, the agency relationship, the label and the commitments that follow approval.

  • Manufacturing & Quality

    Making the drug reliably at scale under CGMP, and proving it to inspectors.

  • Medical Affairs & Commercial

    Scientific exchange with physicians, plus launch, pricing and market access for an approved product.

Pharmaceutical Jobs & Salaries

Six federal occupation codes cover most paid work inside the industry. They are not one ladder: technicians, scientists and managers are counted separately and entered differently, and the highest median belongs to people leading the work rather than running the assays. Pay is the national May 2025 median.

  • Biological technicians

    $57,510

    74,400 jobs · +7% to 2035

  • Chemists and materials scientists

    $95,060

    93,500 jobs · +7% to 2035

  • Medical scientists

    $103,410

    181,000 jobs · +13% to 2035

  • Industrial production managers

    $126,060

    252,100 jobs · +3% to 2035

  • Biochemists and biophysicists

    $127,410

    35,200 jobs · +12% to 2035

  • Natural sciences managers

    $167,220

    112,200 jobs · +8% to 2035

Source: US Bureau of Labor Statistics, Occupational Outlook Handbook, May 2025 wage data, accessed October 2026.

Pharmaceutical Career Paths

Pharma is not one ladder. It is four tracks that share a pipeline and then diverge sharply in what they own, what they pay and how close they sit to the molecule itself.

  1. Clinical Trial Assistant0 to 2 yearsTrial master file, site correspondence and tracking. Measured on completeness, not judgement.
  2. Clinical Research Associate2 to 6 yearsMonitor sites on the sponsor's behalf: source verification, deviations, and whether a site can be trusted.
  3. Clinical Trial Manager6 to 10 yearsOwn one study end to end, including vendors, budget and the enrolment forecast you have to defend.
  4. Director, Clinical Operations10 or more yearsA portfolio of studies and the people running them. Judgement about feasibility rather than about sites.

Credential that fits ACRP certification, CCRC for sites or CCRA for monitoring

There is no federal occupation code for a clinical research associate, a regulatory affairs manager or a medical science liaison, which is why the pay table on this page uses the science and management codes instead. Pharmaceutical selling is counted under sales representatives, wholesale and manufacturing, a 1,571,400-job occupation at a median of $76,460 projected to show little or no change to 2035, where pharmaceuticals sit in the technical and scientific products group.

A Typical Day in Pharmaceutical Jobs

Five roles that carry much of the industry's headcount, ordered from a first laboratory job to a function lead. The schedules are representative rather than universal: therapeutic area, company size and trial phase move everything.

Research AssociateEntry-Level · DiscoveryBench work against a target, and the notebook that makes it count for anything later.
  1. 08:30Read yesterday's plates, flag anything that disagrees with the expected curve before setting up again.
  2. 09:30Assay setup. Most of the skill is reproducibility, so the protocol is followed rather than improved.
  3. 12:30Notebook written up contemporaneously, because retrospective entries are what audits find.
  4. 14:00Team meeting on the series: which compounds advance, which are dropped, what gets made next.
  5. 16:00Second run, plus the housekeeping on reagents and equipment logs that nobody thanks you for.
Clinical Research AssociateMid-Level · Clinical OperationsMonitoring trial sites on the sponsor's behalf, which means being the person who finds the problem.
  1. 08:00Prepare for a monitoring visit: open queries, last report's actions, the subjects you intend to review.
  2. 09:30On site. Source data verification against the case report forms, and the consent files first.
  3. 13:00Sit with the coordinator on protocol deviations and the ones that need reporting upward.
  4. 15:30Drug accountability and temperature logs, which is where the unglamorous findings come from.
  5. 17:00Write the visit report while it is fresh. A late report is a finding of its own.
Regulatory Affairs ManagerMid-Level · RegulatoryThe product's filings, the agency correspondence, and the commitments that outlive the approval.
  1. 08:30Check the agency portal and the commitment tracker for anything with a date attached this month.
  2. 10:00Draft a response to an information request, chasing the clinical and CMC inputs it depends on.
  3. 13:00Review promotional material against the label, because a claim the label does not carry cannot ship.
  4. 15:00Read a new guidance properly and write the half-page on what it changes for this product.
  5. 16:30Submission planning: who owns which module, and which date is genuinely at risk.
Medical Science LiaisonSenior-Level · Medical AffairsScientific exchange with specialists in a territory, inside promotional rules that are enforced.
  1. 07:30Prepare for two appointments: recent publications, the physician's own trial involvement, open questions.
  2. 09:30First meeting. Non-promotional discussion of the data, including where it is weak.
  3. 12:00Log the interaction and route any unsolicited request to medical information rather than answering off label.
  4. 14:00Investigator-initiated study conversation, and an honest view of whether it will be supported.
  5. 17:00Write up field insights that the medical plan needs and that no other function collects.
Director, Clinical OperationsSenior-Level · Function LeadA portfolio of studies, the people running them, and the forecasts other functions plan against.
  1. 08:00Portfolio review: enrolment against plan for every active study, and which forecast you now disbelieve.
  2. 10:00Vendor governance with a contract research organisation, on quality metrics rather than invoices.
  3. 12:30One to ones. Retention is the number this job is actually judged on.
  4. 14:30Programme team, defending a timeline to regulatory and commercial with the assumptions exposed.
  5. 16:30Inspection readiness review on the study closest to filing, file by file.

JOB SEARCH

How to Get a Pharmaceutical Industry Job in 2026

Whether you are leaving the laboratory for industry, moving between functions, or deciding whether the next step is a programme or a department, the questions change with the stage. Pick your level.

Entry-Level

Break Into the Pharmaceutical Industry

What the pipeline is, which functions take people with no industry record, how much education you actually need, and the two standards your work will be measured against from the first week.

What you should know about the field

The shape of the pipeline, what each entry route requires, and the regulations that govern how work is recorded.

What the development pipeline actually looks like

Preclinical work establishes dosing and toxicity in vitro and in vivo before anything reaches a person, under good laboratory practice regulations that govern study conduct, personnel, facilities, protocols, standard operating procedures, reports and quality assurance oversight. Then three trial phases: phase 1 in roughly 20 to 100 participants over several months for safety and dosage, phase 2 in up to several hundred patients over several months to two years for efficacy and side effects, and phase 3 in 300 to 3,000 patients over one to four years.

Learn those numbers early, because almost every job in the industry is defined by which of those boxes it sits in and which document it hands to the next one.

Sources:

Entry is a bachelor's degree far more often than a doctorate

The federal data is explicit about this and it contradicts the folklore. Biological technicians and chemists both show a bachelor's degree as typical entry-level education. Natural sciences managers also show a bachelor's, plus five years or more of related experience. The doctorate requirement is real but narrow: it applies to medical scientists and to biochemists and biophysicists, which is discovery and translational science rather than the industry as a whole.

So the honest reading is that a doctorate buys you a lane, not the building. If you want clinical operations, regulatory affairs, quality or commercial, three years of real work will do more for you than three more years of study.

Sources:

The functions you can enter, and what each one owns

Clinical operations splits between coordinators who run trial activity at a site under a principal investigator and monitors who supervise trials on the sponsor's behalf, which the Association of Clinical Research Professionals treats as two separate credentials for exactly that reason. Regulatory affairs owns the submission and the agency relationship, and the Regulatory Affairs Professionals Society counts quality assurance, quality control, approval-linked clinical research and health product project management as adjacent experience that qualifies you for it.

Commercial is the fourth door. The Bureau of Labor Statistics groups pharmaceutical selling under technical and scientific products, where a bachelor's degree is the normal requirement rather than the exception, and the whole promotional side sits under an FDA office that reviews advertising and promotional labeling to confirm it is truthful, balanced and not misleading.

Sources:

GLP and GCP are the two acronyms you will be judged on

Good laboratory practice is a regulation, cited by FDA at 21 CFR 58.1, setting minimum requirements for how a preclinical study is run and recorded. Good clinical practice is its clinical equivalent: FDA issued ICH E6(R3) as final guidance in September 2025 through its drug and biologics centres, revising GCP around quality by design, risk-based quality management and proportionality, with sponsor and investigator responsibilities clarified.

The practical consequence for a new joiner is that nothing you do counts unless it is documented the way the standard expects. Work that happened but cannot be shown to have happened did not happen.

Sources:

Skills employers look for

What a hiring manager checks on someone with no track record, beyond the degree itself.

Documentation that survives an audit

Contemporaneous, attributable, legible and complete. The good laboratory practice regulations name written protocols, standard operating procedures, study reports and quality assurance oversight as requirements rather than good habits, and that posture carries through every regulated function in the industry.

Sources:

Protocol and SOP literacy

Reading a protocol and knowing which parts are negotiable, which are commitments and which are the ones a monitor will check first. ICH E6(R3) pushes proportionality, which only helps you if you can tell the critical requirements from the rest.

Source:

Data handling and endpoint discipline

Understanding what a primary endpoint is and why a late definition change is expensive. FDA inspectors visit study sites specifically to look for fabricated, manipulated or withheld data, so sloppiness in a dataset is a compliance matter long before it is a statistics one.

Sources:

Scientific writing for a regulated reader

A new drug application carries all the data from preclinical work through phase 3 plus proposed labeling, safety updates and directions for use. Everything in it was drafted by somebody, and people who write clearly for a reviewer become useful much faster than their job title suggests.

Source:

Interview questions and answers

Questions new entrants actually get, and what the panel is listening for underneath them.

Walk me through how a drug gets from a target to a label.

What they are looking for: Whether you know the stage gates and the documents, not whether you can recite biology. They are testing industry literacy.

Preclinical work establishes toxicity and dosing, then phase 1 looks at safety and dose in a small group, phase 2 at efficacy and side effects in a few hundred patients, phase 3 at efficacy in up to three thousand. The sponsor then files a new drug application with everything from preclinical through phase 3 plus proposed labeling, FDA decides whether to file it, and the label itself is negotiated with the agency.

Make it yours: Name the documents, not just the phases. Candidates who say IND, protocol, clinical study report and label sound like they have worked here; candidates who only say phase one, two, three sound like they read a diagram.

Why the industry rather than academia or the clinic?

What they are looking for: A reason that survives contact with the work: scale, timelines, teams, regulated rigour. They are screening for people who will leave in a year.

In the lab I liked the experiment and disliked that nothing I did reached anyone. Here the constraint is not curiosity, it is evidence that a regulator will accept, and I would rather work on the version of a question that has a patient at the end of it, even if that means working inside a protocol somebody else wrote.

Make it yours: Be specific about what you are leaving and honest that you are trading autonomy for reach. Answers built on pay or stability read badly even when they are true.

Tell me about a time someone else checked your work and found a problem.

What they are looking for: Whether you can be corrected without defending, and whether you fixed the system or only the instance.

A supervisor reviewing my notebook found I had recorded two incubation times from memory at the end of the day rather than as they happened. I corrected and annotated the entries, then moved to writing times down on a bench sheet in the moment. The second part is what mattered: the first error was carelessness, repeating it would have been a process failure.

Make it yours: Pick a real finding, however small, and spend most of the answer on the change you made. An answer with no finding in it reads as someone who has never been audited.

A monitor finds a consent form signed after the first study procedure. What now?

What they are looking for: That you escalate rather than tidy, and that you understand this as a participant-protection issue rather than paperwork.

I would stop and document what I found, report it to the principal investigator and the sponsor as a deviation, and notify the review board according to the protocol and our standard operating procedure. I would not alter the form. Then I would look at how the sequence was allowed to happen, because the fix is in the site workflow, not in that one file.

Make it yours: Say the word deviation and say who you tell. Any answer that starts by making the file look right is disqualifying.

Why Pharmaceutical Professionals Need to Stay Informed

Approvals, trial readouts, agency guidance and payer decisions all arrive from outside your company, and all of them reset your plan. Staying current is how you see a competitor's miss, a changed evidence standard or a pricing decision in time to act on it rather than react to it.

Read more

The second reason is structural. Restructuring, site closures and portfolio resets are reported in the trade press weeks before they reach an org chart, and the people who move early are the ones who were reading.

The bottom line

The Industry Is Stable. Its Employers Are Not.

The occupations pharma draws on are projected to grow between 3 and 13 percent to 2035, while any single programme can end on one readout. A career here is built on skills that move between companies, and on reading the field before your own employer does.

Stay Informed with Hark's Pharma Briefing

How it works

  1. Pick the newsletters you want

    Choose from our handpicked list, or add your own. See the picks

  2. We subscribe you properly

    Each one arrives at your own private Hark address, never your inbox.

  3. We read them so you do not have to

    Every issue is distilled into one short script each morning.

  4. You listen on the way in

    A text arrives with a link. Five minutes, then you are current.

The 4 Pharma Newsletters We Handpicked

  1. BioPharma Dive Daily Dive

    Industry Dive

    • Free
    • Weekdays
    • 206k readers

    Industry Dive's free weekday briefing on biotech and pharma, tracking clinical trials, FDA actions, and dealmaking for people inside the industry.

    Why pharmaceutical professionals read it

    Industry Dive's free weekday briefing tracking clinical trials, regulatory actions and dealmaking for people inside the industry, read by more than 200,000 of them. It is the most complete daily view of the sector and the natural anchor here.

    Listen to BioPharma Dive Daily Dive free

    More about this newsletter

    BioPharma Dive is Industry Dive's free weekday briefing on biotech and pharma: clinical trial readouts, FDA actions, and dealmaking, written for people inside the industry. Its advertising page claims 206,000 newsletter subscribers. The accessible end of the biopharma trade press.

    Best for: Biopharma professionals who want a free weekday briefing on clinical trial readouts, FDA actions, and dealmaking written for people inside the industry.

  2. Fierce Pharma / Fierce Biotech

    Questex

    • Free
    • Daily

    Long-running flagship free daily on pharma and biotech industry news.

    Why pharmaceutical professionals read it

    The long-running flagship daily on pharma and biotech industry news. Its commercial coverage, on launches, marketing and manufacturing, runs deeper than the science-first sources, which is why it earns a slot alongside them.

    Listen to Fierce Pharma / Fierce Biotech free

    More about this newsletter

    Fierce Pharma and Fierce Biotech are the long-running flagship dailies of the drug-industry trade press, covering pharma marketing, manufacturing, clinical results, and biotech financing each weekday morning. High volume and comprehensive. The default inbox presence for industry professionals.

    Best for: Industry professionals who want comprehensive, high-volume daily coverage of pharma marketing, manufacturing, and biotech financing every weekday morning.

See the other 2 newsletters
  1. Endpoints News

    Endpoints News

    • Freemium
    • daily

    Daily biotech and pharma industry news: drug development, FDA decisions, deals, and the business of medicine.

    Why pharmaceutical professionals read it

    A daily on drug development, agency decisions, deals and the business of medicine, written for an industry audience. It tends to carry the reporting on financing and strategy that determines which programs continue.

    Listen to Endpoints News free

    More about this newsletter

    Endpoints News is a dedicated biopharma newsroom whose daily emails track drug development, FDA decisions, and dealmaking with wire-service speed and real sourcing. The core newsletters are free; deeper reporting sits behind an Endpoints subscription. A must-follow for anyone serious about the drug industry.

    Best for: Drug industry followers who want wire-service speed and real sourcing on drug development, FDA decisions, and dealmaking from a dedicated biopharma newsroom.

  2. The Readout

    STAT (Boston Globe Media)

    • Free
    • Weekdays

    STAT's free weekday morning newsletter on the science, politics, and money driving biotech, written by STAT's biotech reporters.

    Why pharmaceutical professionals read it

    STAT's free weekday morning newsletter on the science, politics and money driving biotech, from reporters who cover the field full time. It is the strongest of these on the science itself and on how policy will treat it.

    Listen to The Readout free

    More about this newsletter

    The Readout lands every weekday morning with a rundown of biotech news: clinical readouts, FDA decisions, deals, and market moves, linking to STAT's reporting. The signup page currently credits reporters Meghana Keshavan and Elaine Chen. The newsletter itself is free, though some linked stories sit behind the STAT+ paywall.

Frequently Asked Questions

Entry-Level

What does a pharmaceutical professional actually do day to day?

It depends entirely on which box of the pipeline you sit in, which is why the job title matters more here than the industry name. A research associate runs assays and records them; a clinical research associate visits trial sites and verifies source data against the case report forms; a regulatory affairs manager drafts agency responses and checks promotional claims against the label; a quality professional owns whether a facility is defensible to an inspector. What they share is that almost every output is a document somebody else will audit, and that the work is sequenced by stage gates rather than by your own calendar.

Is the pharmaceutical industry a good career in 2026 and beyond?

On the federal projections, the occupations it draws on are all growing: medical scientists 13 percent to 2035, biochemists and biophysicists 12 percent, chemists and biological technicians 7 percent each, natural sciences managers 8 percent, industrial production managers 3 percent. The caution is that the sector is stable while individual employers are not, because a programme can end on one readout and restructuring follows pipeline resets. Treat it as a good industry with volatile employers, and build the kind of function-specific skill that moves to the next company without renegotiation.

How do you get your first job in the pharmaceutical industry?

Three doors open most often. Laboratory roles, where a bachelor's degree is the typical entry-level education for biological technicians and chemists. Clinical operations, usually via a trial assistant or site coordinator post, which is why the Association of Clinical Research Professionals maintains a separate coordinator credential. And regulatory or quality support, where the Regulatory Affairs Professionals Society explicitly counts quality assurance, quality control and approval-linked clinical research as qualifying experience. Contract research organisations and contract manufacturers hire at volume and are the least credential-bound starting point, which makes them the usual first employer rather than the brand you have heard of.

What is the difference between pharma, biotech and a contract research organisation?

Large pharma owns a marketed portfolio and runs discovery through commercial under one roof, so roles are narrower and the process is heavier. Biotech is usually earlier, smaller and financed against readouts, so roles are broader and employment is tied more tightly to a single programme. A contract research organisation or contract manufacturer sells capability to both: you run other companies' trials or make other companies' products. The work is often the same work, but the CRO route gives you more studies and more therapeutic areas faster, at the cost of owning none of them.

Do you need a PhD or a PharmD to work in pharma?

No, and the federal data is unusually clear on it. A doctoral or professional degree is listed as the typical entry-level education for medical scientists and for biochemists and biophysicists, which is discovery and translational science. Biological technicians, chemists and even natural sciences managers show a bachelor's degree, with the managers also needing five years or more of related experience. A doctorate buys you a particular lane rather than the industry, and a PharmD or MD matters most in medical affairs. For clinical operations, regulatory, quality and commercial, experience and a recognised certification go further.

Which degrees and entry-level titles lead into drug development?

Life sciences, chemistry, pharmacy, nursing, statistics and engineering all feed in, and the degree matters less than the first title you can get. The entry titles that lead somewhere are research associate, clinical trial assistant, clinical research coordinator, regulatory affairs associate, quality assurance associate, medical information associate and manufacturing or laboratory technician. For the commercial side, pharmaceutical selling is classified under technical and scientific products, where a bachelor's degree is the normal requirement. Pick the title closest to the function you want, because moving functions later is harder than moving companies.

What are the clinical trial phases, and which teams work on each?

Phase 1 runs in roughly 20 to 100 participants over several months and looks at safety and dosage, with about 70 percent of drugs advancing. Phase 2 runs in up to several hundred patients over several months to two years on efficacy and side effects, and about 33 percent advance. Phase 3 runs in 300 to 3,000 patients over one to four years, with 25 to 30 percent advancing. Phase 4 follows approval in several thousand patients. Clinical pharmacology and operations dominate phase 1, clinical development and biostatistics phase 2, operations and data management phase 3, and pharmacovigilance and medical affairs phase 4.

Get Tomorrow's Pharma Briefing

BioPharma Dive reaches over 200,000 industry readers each weekday and The Readout puts STAT's biotech desk in the same inboxes as your competitors' teams. When a readout drops, the people across the street have already read three takes on what it means for your program.